Hello and welcome to today’s live coverage of the coronavirus with me, Helen Sullivan.
As always, you can find me on Twitter @helenrsullivan.
Canada will receive a significant amount of vaccines in the coming months through a platform designed to maximize delivery to poor countries, according to a new forecast, despite reserving the most doses per person in the world through direct deals with pharmaceutical companies.
The Globe and Mail reports that Canada will be the only G7 country in the world to accept vaccines from the program.
My colleagues Michael Safi and Leyland Cecco report that Canada has the right to receive injections under the Covax program, which uses advance purchases by rich countries to support vaccine development and subsidize doses for poorer countries.
But Ottawa has also led the world into direct deals with drug companies to secure its own supplies, and according to a Guardian analysis, enough is reserved for about 9.6 doses per person.
More about this shortly. For now, here are the other major recent developments:
- Regulatory authorities in Belgium are the latest in Europe to advise against administration of the Oxford / AstraZeneca vaccine to the elderly due to lack of efficacy data.
- SwitZerland has withheld approval for Oxford / AstraZeneca’s Covid vaccine, his drug regulator said today.
- Leaders in Europe are recklessly putting the health of their own people at risk by using self-service point scoring to attack the introduction of the UK’s coronavirus vaccine, British health experts have warned. “The views of politicians in Europe are in stark contrast to the scientific view of the European regulator,” said a former head of the drug regulator.
- New coronavirus infections in Greece have increased by more than 1,000 for the second consecutive day, with health authorities adding 1,151 to the country’s census after a month of the daily figure remaining in the triple digits.
- Veterinarians in Germany have trained detection dogs to detect the corona virus in human saliva samples with an accuracy of 94%.
- The Covax facility schedule aims to distribute at least 330 million doses by the first half of 2021, the co-leaders announced Wednesday. It has also signed a deal with the Serum Institute of India for up to 1.1 billion doses of AstraZeneca and Novavax vaccines at $ 3 per dose for low- and middle-income countries.
- AstraZeneca and Oxford University are aiming to develop a next-generation vaccine as early as the fall to address new variants. a senior executive at the manufacturer told Reuters.